Completado

IMPAACT 1092: Phase IV Evaluation Of The Steady State Pharmacokinetics Of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in Severely Malnourished HIV-1-Infected Children

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

ZDV+3TC+LPV/r

+ ZDV+3TC+LPV/r

Medicamento
Quiénes están siendo reclutados

Infecciones Transmitidas por la Sangre+13

+ Enfermedades Urogenitales

+ Enfermedades Genitales

Entre 6 y 36 meses
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Tratamiento

Fase 4
Intervencional
Inicio del estudio: octubre de 2015
Ver detalles del protocolo

Resumen

Patrocinador PrincipalInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group
Última actualización: 12 de agosto de 2021
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 26 de octubre de 2015

Fecha en la que se inscribió al primer participante.

P1092 was a prospective, non-randomized Phase IV open label study of antiretroviral drugs zidovudine (ZDV), lamivudine (3TC), and ritonavir boosted lopinavir (LPV/r) in children living with HIV aged 6 to less than 36 months grouped by nutritional status. The study's primary objectives were to characterize the pharmacokinetics (PK), safety, and tolerability of antiretroviral (ARV) regimens in severely acute malnourished (SAM) children following the initiation of nutritional rehabilitation and compare results to mildly malnourished or normally nourished children in order to determine if current recommended doses are optimal in severely malnourished children. Two cohorts of children were enrolled based on nutritional status at screening: severely acute malnourished children and children with mild malnutrition or normal nutrition (non-SAM cohort). SAM participants were recruited from nutritional rehabilitation clinics while non-SAM participants were enrolled from HIV treatment centers. SAM participants were required to complete a 10 to 18 day nutritional rehabilitation program before entering the study. A World Health Organization (WHO, 2013) approach to management of SAM was used. All participants were to receive an antiretroviral regimen of ZDV+3TC+LPV/r. ARVs were dosed based on WHO weight band dosing and were to be administered twice per day in a pediatric liquid formulation. ZDV was allowed to be replaced with abacavir at the discretion of the site investigator/clinician in cases of grade 3 or higher hematologic toxicity on a ZDV-inclusive regimen or ZDV intolerance. Participants were followed for 48 weeks.

NCT01818258
Patrocinador PrincipalInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group
Última actualización: 12 de agosto de 2021
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 52 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio de Tratamiento

Estos estudios prueban nuevas formas de tratar una enfermedad, condición o problema de salud. El objetivo es determinar si un nuevo medicamento, terapia o enfoque funciona mejor o tiene menos efectos secundarios que las opciones existentes.


Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

Entre 6 y 36 meses

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

Infecciones Transmitidas por la SangreEnfermedades UrogenitalesEnfermedades GenitalesEnfermedades TransmisiblesSíndromes de Deficiencia InmunológicaEnfermedades del sistema inmunitarioInfeccionesTrastornos de la NutriciónEnfermedades Nutricionales y MetabólicasInfecciones por RetroviridaeInfecciones por virus de ARNEnfermedades de Transmisión SexualEnfermedades ViralesEnfermedades de transmisión sexual, viralesInfecciones por VIHSeropositividad del VIH

Criterios

Inclusion Criteria: Documentation of HIV-1 infection defined as positive results from two samples collected at different time points, using protocol-specified tests Meets WHO classification for severe malnutrition, normal nutrition status, or mild malnutrition Eligible for HAART defined by WHO 2013 pediatric guidelines Parent or legal guardian able and willing to provide signed informed consent, remain within the study area during the study period and agree to have subject followed at the clinical site Qualifying hematology and chemistry laboratory values obtained from specimens collected within the study-specific screening period For severely malnourished children: An inpatient in a nutrition rehabilitation unit. Clinical improvement after 10-18 days on nutrition rehabilitation defined as: Appetite returned and eating better - child shows interest in food even if does not complete amount given: No further weight loss Normalized sodium and potassium defined as severity grade 1 or lower No evidence of cardiac failure Loss of apathy and starting to play No hypothermia or pyrexia - temperature stable at >35.0 to <38.0° C (non-axillary) or >34.4 to <37.4° C (axillary) For children with normal - mild malnutrition, clinical stability will be indicated by: Good appetite Normalized sodium and potassium defined as severity grade 1 or lower No hypothermia or pyrexia - temperature stable at >35.0 to <38.0° C (non-axillary) or >34.4 to <37.4° C (axillary) Exclusion Criteria: Edematous malnutrition at the time of study entry ≥ Grade 3 respiratory distress or presence of cardio respiratory compromise within 3 days prior to entry Chemotherapy for malignancy Acute infection for which the child has received appropriate antimicrobial treatment for <5 days Tuberculosis disease Clinic hepatitis as evidenced by jaundice and hepatomegaly Taking any disallowed medications Any condition, situation, or clinical finding that in the opinion of the investigator would place the child at an unacceptable level of risk for injury, or render the child/caregiver(s) unable to meet the requirements of the study, interfere with study participation, or in the interpretation of study results.

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

2 grupos de intervención están designados en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Comparador Activo
ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks

Grupo II

Comparador Activo
ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene 5 ubicaciones

Blantyre CRS (30301)

Blantyre, MalawiAbrir Blantyre CRS (30301) en Google Maps

Malawi CRS (12001)

Lilongwe, Malawi

Kilimanjaro Christian Medical Centre (5118)

Moshi, Tanzania

Makerere University-Johns Hopkins University (MUJHU) Research Collaboration (30293)

Kampala, Uganda
Completado5 Centros de Estudio